261 related articles for article (PubMed ID: 25989210)
21. Mechanism-specific signatures for small-molecule p53 activators.
van Leeuwen IM; Higgins M; Campbell J; Brown CJ; McCarthy AR; Pirrie L; Westwood NJ; Laín S
Cell Cycle; 2011 May; 10(10):1590-8. PubMed ID: 21490429
[TBL] [Abstract][Full Text] [Related]
22. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
[TBL] [Abstract][Full Text] [Related]
23. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.
Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P
J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964
[TBL] [Abstract][Full Text] [Related]
24. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
[TBL] [Abstract][Full Text] [Related]
25. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
[TBL] [Abstract][Full Text] [Related]
26. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.
Duan L; Perez RE; Lai X; Chen L; Maki CG
J Biol Chem; 2019 Jun; 294(23):9186-9197. PubMed ID: 31036564
[TBL] [Abstract][Full Text] [Related]
27. The hydrophobically-tagged MDM2-p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a.
Nietzold F; Rubner S; Berg T
Chem Commun (Camb); 2019 Nov; 55(95):14351-14354. PubMed ID: 31720601
[TBL] [Abstract][Full Text] [Related]
28. Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner.
Shuvalov O; Kizenko A; Shakirova A; Fedorova O; Petukhov A; Aksenov N; Vasileva E; Daks A; Barlev N
Biochem Biophys Res Commun; 2018 Jan; 495(1):1233-1239. PubMed ID: 29175211
[TBL] [Abstract][Full Text] [Related]
29. Nutlin-3a is a potential therapeutic for ewing sarcoma.
Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
[TBL] [Abstract][Full Text] [Related]
30. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
31. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
Tseng HY; Jiang CC; Croft A; Tay KH; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Mol Cancer Ther; 2010 Dec; 9(12):3363-74. PubMed ID: 21159614
[TBL] [Abstract][Full Text] [Related]
32. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.
Drakos E; Atsaves V; Li J; Leventaki V; Andreeff M; Medeiros LJ; Rassidakis GZ
Leukemia; 2009 Apr; 23(4):784-90. PubMed ID: 19225536
[TBL] [Abstract][Full Text] [Related]
33. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
Villalonga-Planells R; Coll-Mulet L; Martínez-Soler F; Castaño E; Acebes JJ; Giménez-Bonafé P; Gil J; Tortosa A
PLoS One; 2011 Apr; 6(4):e18588. PubMed ID: 21483692
[TBL] [Abstract][Full Text] [Related]
34. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
Kojima K; Konopleva M; Samudio IJ; Ruvolo V; Andreeff M
Cancer Res; 2007 Apr; 67(7):3210-9. PubMed ID: 17409429
[TBL] [Abstract][Full Text] [Related]
35. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Zanjirband M; Edmondson RJ; Lunec J
Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
[TBL] [Abstract][Full Text] [Related]
36. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
[TBL] [Abstract][Full Text] [Related]
37. On p53 revival using system oriented drug dosage design.
Haseeb M; Azam S; Bhatti AI; Azam R; Ullah M; Fazal S
J Theor Biol; 2017 Feb; 415():53-57. PubMed ID: 27979498
[TBL] [Abstract][Full Text] [Related]
38. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
39. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation.
Valentine JM; Kumar S; Moumen A
BMC Cancer; 2011 Feb; 11():79. PubMed ID: 21338495
[TBL] [Abstract][Full Text] [Related]
40. MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition.
Schneider LS; Ulrich M; Lehr T; Menche D; Müller R; von Schwarzenberg K
Mol Oncol; 2016 Aug; 10(7):1054-62. PubMed ID: 27157929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
